Formulating for Complexity: A Strategic Guide for Challenging Early-Phase Molecules

The right formulation choices unlock clinical momentum, capital efficiency, and future flexibility. The wrong ones create manufacturability barriers and derail the path to scale-up. And when investor confidence hinges on clinical milestones, one misstep can mean a loss of faith and funding.

This guide is for pharmaceutical executives navigating early drug development, helping them set the stage for faster approvals, smoother launches, and a stronger story for both regulators and investors.